ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199

Product List

Home / ARPOD-CV DRY SYP

MEFIMIC-P DS SUSP

Product Packing: 60 ML

Product Composition: Mefenemic Acid 100 mg + Paracetamol 250 mg

Product Price: MRP :

MEFIMIC-P DS Suspension

Mefenamic Acid 100 mg + Paracetamol 250 mg Suspension | 60 ml

MEFIMIC-P DS is an oral suspension containing Mefenamic Acid 100 mg and Paracetamol 250 mg as the declared combination strength. Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory actions, while Paracetamol is an analgesic and antipyretic. The combination may be used for short-term symptomatic relief of pain and fever where approved and clinically appropriate.

Mefenamic Acid reduces prostaglandin synthesis through cyclo-oxygenase inhibition, while Paracetamol acts mainly within the central nervous system to reduce pain perception and elevated body temperature. Dosing must follow the exact approved concentration per measured volume, age/weight requirements and professional advice.

Composition

Each labelled dose contains:

· Mefenamic Acid - 100 mg

· Paracetamol - 250 mg

· Suspension base / excipients - q.s. Exact strength per ml or per measured dose must be verified from the approved product label.

Dosage form: Oral Suspension

Pack size: 60 ml

Uses of MEFIMIC-P DS

MEFIMIC-P DS may be used for short-term symptomatic relief of pain and fever where the Mefenamic Acid + Paracetamol combination is approved and clinically appropriate.

· Helps reduce mild to moderate pain according to approved prescribing information

· Helps reduce fever through the antipyretic action of Paracetamol

· Mefenamic Acid contributes analgesic and anti-inflammatory activity where inflammation is associated with pain

· Liquid suspension allows accurately measured administration according to the approved dose

This combination treats symptoms but does not treat the underlying cause. Persistent, severe or recurrent pain or fever requires medical evaluation.

How MEFIMIC-P DS Works

MEFIMIC-P DS combines two complementary pain- and fever-relieving mechanisms:

Mefenamic Acid: An NSAID that inhibits cyclo-oxygenase enzymes and reduces prostaglandin synthesis, helping relieve pain and inflammation.

Paracetamol: Acts mainly centrally to reduce pain perception and lower elevated body temperature.

Combined action: The two components can provide complementary symptomatic relief when combination therapy is clinically appropriate.

Clinical response depends on the cause of symptoms, correctly measured dose, treatment duration and individual patient factors.

The total daily exposure to Mefenamic Acid, Paracetamol and other NSAID- or Paracetamol-containing medicines must be considered to avoid duplicate dosing.

Dosage and Direction for Use

Use MEFIMIC-P DS exactly according to the approved product label or healthcare professional's directions. The dose must be based on the exact concentration per measured volume, age, weight and clinical situation.

Shake the suspension well before each dose and measure it with a calibrated oral syringe, cup or other appropriate measuring device.

Mefenamic Acid is generally intended for short-term use. Give with food or as directed to reduce gastrointestinal discomfort, and never exceed the labelled or prescribed dose or duration.

Do not combine with another NSAID or Paracetamol/Acetaminophen-containing medicine unless specifically advised by a healthcare professional.

Possible Side Effects

Possible unwanted effects may include:

· Nausea, vomiting, abdominal discomfort, indigestion or diarrhoea

· Headache, dizziness or mild skin reactions

· Mefenamic Acid can cause gastric irritation, ulceration or gastrointestinal bleeding, particularly in susceptible patients or with excessive/prolonged use

· Excessive Paracetamol dosing can cause serious liver injury; NSAIDs can also affect kidney function, fluid balance and cardiovascular risk in susceptible patients

· Seek urgent medical attention for suspected overdose, vomiting blood, black stools, severe abdominal pain, breathing difficulty, facial swelling, severe rash, markedly reduced urination or jaundice.

Persistent or troublesome adverse effects should be discussed with a healthcare professional.

Precautions and Contraindications

Before using MEFIMIC-P DS, review age, weight, dehydration status, allergy history, stomach-ulcer/bleeding history, asthma, kidney or liver disease and all other medicines being taken.

· Avoid in patients with known hypersensitivity to Mefenamic Acid, Paracetamol, aspirin/other NSAIDs or formulation ingredients according to approved prescribing information.

· NSAIDs require caution in gastrointestinal ulcer/bleeding risk, kidney disease, significant dehydration, cardiovascular disease and patients with NSAID-sensitive asthma.

· Avoid duplicate Paracetamol-containing medicines and avoid using another NSAID at the same time unless specifically prescribed.

· Mefenamic Acid should generally be used for the shortest appropriate duration. Significant dehydration can increase NSAID-related kidney risk.

· Use during pregnancy, especially later pregnancy, requires professional guidance because NSAIDs have important pregnancy-related restrictions.

· Breastfeeding, children, older adults and patients with significant chronic conditions require individualized professional guidance.

· Keep out of reach of children and store according to the approved pack instructions.

· Drug Interaction Considerations

· Clinically relevant interactions may involve anticoagulants/antiplatelets, corticosteroids, other NSAIDs, certain antihypertensives and diuretics, lithium, methotrexate and medicines affecting kidney function. Prolonged regular Paracetamol use may also interact with anticoagulant therapy.

· Patients or caregivers should provide the healthcare professional with a complete list of prescription medicines, OTC products, vitamins and supplements before repeated or prolonged use.

Business Growth Opportunity with MEFIMIC-P DS

MEFIMIC-P DS offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add a Mefenamic Acid 100 mg + Paracetamol 250 mg oral suspension in a 60 ml pack to their pain and fever management portfolio.

Pain and fever management is an established healthcare segment. Promotion and use should remain consistent with approved product information, responsible dosing, ethical pharmaceutical practice and applicable regulations.

Key Business Advantages

· Dual analgesic and antipyretic formulation

· Mefenamic Acid 100 mg + Paracetamol 250 mg

· NSAID + Paracetamol combination

· Convenient 60 ml oral suspension pack

· Suitable addition to pain and fever management portfolios where the combination is approved and clinically appropriate

· Opportunity for ethical promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for MEFIMIC-P DS

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for MEFIMIC-P DS in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Franchise Support May Include

· Monopoly-based territory opportunities, subject to availability

· Promotional materials and visual aids

· Product information and marketing support

· Reliable supply coordination

· Access to a growing pharmaceutical product portfolio

· Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MEFIMIC-P DS and other quality-focused healthcare products.

Third-Party Manufacturing Support for Mefenamic Acid + Paracetamol Suspension

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to MEFIMIC-P DS under their own brand, subject to applicable licensing, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

· Customized product and pack requirements, subject to regulatory feasibility

· Private-label manufacturing opportunities

· Customized packaging and branding support

· Product label and pack configuration assistance

· Manufacturing coordination through suitable licensed facilities

· Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an analgesic and antipyretic liquid portfolio.

Frequently Asked Questions About MEFIMIC-P DS

1. What is MEFIMIC-P DS?

MEFIMIC-P DS is an oral suspension containing Mefenamic Acid 100 mg and Paracetamol 250 mg as the declared combination strength, supplied in a 60 ml pack.

2. What is MEFIMIC-P DS used for?

It may be used for short-term symptomatic relief of pain and fever where this combination is approved and clinically appropriate.

3. How should MEFIMIC-P DS be measured?

Shake well and use a calibrated measuring device. The exact dose must follow the approved concentration, age/weight instructions and healthcare professional's advice.

4. Can MEFIMIC-P DS be given with another pain or fever medicine?

Do not combine it with another NSAID or Paracetamol-containing medicine unless specifically advised, because duplicate dosing can increase serious adverse-effect risk.

5. What are important Mefenamic Acid precautions?

Mefenamic Acid requires caution with stomach ulcers or bleeding, kidney disease, significant dehydration, NSAID-sensitive asthma and certain cardiovascular conditions.

6. What should be done after a suspected overdose?

Seek urgent medical attention immediately, especially because excessive Paracetamol can cause serious liver injury and excessive NSAID exposure can cause gastrointestinal, kidney or other toxicity.

7. Is a PCD Pharma Franchise available for MEFIMIC-P DS?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Mefenamic Acid + Paracetamol suspension may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

MEFIMIC-P DS product information in this document is for general professional and business information. The supplied product brief states Mefenamic Acid 100 mg + Paracetamol 250 mg suspension, 60 ml, but the exact strength per measured volume must be verified from the current approved product label. Exact composition, concentration, approved age range, indications, dosage, dose interval, maximum daily dose, contraindications, warnings, interactions, administration instructions, excipients and regulatory status must be verified before manufacture, promotion, prescribing, dispensing or use. Avoid duplicate NSAID or Paracetamol-containing products. This document is not a substitute for professional medical advice.

Dosage Form

Therapy Wise

MEFIMIC-P DS SUSP

MEFIMIC-P DS Suspension

Mefenamic Acid 100 mg + Paracetamol 250 mg Suspension | 60 ml

Composition

Pack size: 60 ml

This combination treats symptoms but does not treat the underlying cause. Persistent, severe or recurrent pain or fever requires medical evaluation.

Combined action: The two components can provide complementary symptomatic relief when combination therapy is clinically appropriate.

Mefenamic Acid is generally intended for short-term use. Give with food or as directed to reduce gastrointestinal discomfort, and never exceed the labelled or prescribed dose or duration.

· Seek urgent medical attention for suspected overdose, vomiting blood, black stools, severe abdominal pain, breathing difficulty, facial swelling, severe rash, markedly reduced urination or jaundice.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients or caregivers should provide the healthcare professional with a complete list of prescription medicines, OTC products, vitamins and supplements before repeated or prolonged use.

Pain and fever management is an established healthcare segment. Promotion and use should remain consistent with approved product information, responsible dosing, ethical pharmaceutical practice and applicable regulations.

· Opportunity for ethical promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MEFIMIC-P DS and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an analgesic and antipyretic liquid portfolio.

Frequently Asked Questions About MEFIMIC-P DS

MEFIMIC-P DS is an oral suspension containing Mefenamic Acid 100 mg and Paracetamol 250 mg as the declared combination strength, supplied in a 60 ml pack.

It may be used for short-term symptomatic relief of pain and fever where this combination is approved and clinically appropriate.

Shake well and use a calibrated measuring device. The exact dose must follow the approved concentration, age/weight instructions and healthcare professional's advice.

Do not combine it with another NSAID or Paracetamol-containing medicine unless specifically advised, because duplicate dosing can increase serious adverse-effect risk.

Mefenamic Acid requires caution with stomach ulcers or bleeding, kidney disease, significant dehydration, NSAID-sensitive asthma and certain cardiovascular conditions.

Seek urgent medical attention immediately, especially because excessive Paracetamol can cause serious liver injury and excessive NSAID exposure can cause gastrointestinal, kidney or other toxicity.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Mefenamic Acid + Paracetamol suspension may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Dosage Form

Therapy Wise

MEFIMIC-P DS SUSP

MEFIMIC-P DS Suspension

Mefenamic Acid 100 mg + Paracetamol 250 mg Suspension | 60 ml

Composition

Pack size: 60 ml

This combination treats symptoms but does not treat the underlying cause. Persistent, severe or recurrent pain or fever requires medical evaluation.

Combined action: The two components can provide complementary symptomatic relief when combination therapy is clinically appropriate.

Mefenamic Acid is generally intended for short-term use. Give with food or as directed to reduce gastrointestinal discomfort, and never exceed the labelled or prescribed dose or duration.

· Seek urgent medical attention for suspected overdose, vomiting blood, black stools, severe abdominal pain, breathing difficulty, facial swelling, severe rash, markedly reduced urination or jaundice.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients or caregivers should provide the healthcare professional with a complete list of prescription medicines, OTC products, vitamins and supplements before repeated or prolonged use.

Pain and fever management is an established healthcare segment. Promotion and use should remain consistent with approved product information, responsible dosing, ethical pharmaceutical practice and applicable regulations.

· Opportunity for ethical promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MEFIMIC-P DS and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an analgesic and antipyretic liquid portfolio.

Frequently Asked Questions About MEFIMIC-P DS

MEFIMIC-P DS is an oral suspension containing Mefenamic Acid 100 mg and Paracetamol 250 mg as the declared combination strength, supplied in a 60 ml pack.

It may be used for short-term symptomatic relief of pain and fever where this combination is approved and clinically appropriate.

Shake well and use a calibrated measuring device. The exact dose must follow the approved concentration, age/weight instructions and healthcare professional's advice.

Do not combine it with another NSAID or Paracetamol-containing medicine unless specifically advised, because duplicate dosing can increase serious adverse-effect risk.

Mefenamic Acid requires caution with stomach ulcers or bleeding, kidney disease, significant dehydration, NSAID-sensitive asthma and certain cardiovascular conditions.

Seek urgent medical attention immediately, especially because excessive Paracetamol can cause serious liver injury and excessive NSAID exposure can cause gastrointestinal, kidney or other toxicity.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Mefenamic Acid + Paracetamol suspension may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

We value your privacy

Get the Product Details